Therapeutic options for cervicogenic headache.

Abstract:

:The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve blocks, cervical nerve blockades, facet joint injections and surgical procedures is limited. Several physical therapy interventions are proposed for CeH, with spinal manipulation and soft tissue interventions being the most commonly used. However, the lack of solid evidence of positive effects and risks of serious complications for spinal manipulation should be considered in favor of other physical therapy interventions associated with less risk. The inconsistent results in the literature can be related to the fact that maybe not all therapeutic interventions are appropriate for all patients with CeH or maybe not all patients with CeH will benefit from particular interventions.

journal_name

Expert Rev Neurother

authors

Fernández-de-las-Peñas C,Cuadrado ML

doi

10.1586/14737175.2014.863710

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

39-49

issue

1

eissn

1473-7175

issn

1744-8360

journal_volume

14

pub_type

杂志文章,评审
  • Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.

    abstract::Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1847085

    authors: Ng HS,Zhu F,Kingwell E,Zhao Y,Yao S,Ekuma O,Svenson LW,Evans C,Fisk JD,Marrie RA,Tremlett H

    更新日期:2021-01-01 00:00:00

  • Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?

    abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.111

    authors: Dennison L,Moss-Morris R

    更新日期:2010-09-01 00:00:00

  • Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

    abstract:INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1326818

    authors: Khan A,Corbett A,Ballard C

    更新日期:2017-07-01 00:00:00

  • Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.

    abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.988709

    authors: Prakash A,Kalra J,Mani V,Ramasamy K,Majeed AB

    更新日期:2015-01-01 00:00:00

  • Pharmacological treatment of trigeminal neuralgia.

    abstract:INTRODUCTION:Unique among the different neuropathic pain conditions, trigeminal neuralgia frequently has an excellent response to some selected drugs, which, on the other hand, often entail disabling side effects. Physicians should be therefore acquainted with the management of these drugs and the few alternative optio...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1370375

    authors: Di Stefano G,Truini A

    更新日期:2017-10-01 00:00:00

  • Triptanophobia in migraine: A case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients.

    abstract::Background: Triptanophobia is the excessive and inadequately justified concern about potential risks of triptans. We evaluated causes and consequences of nonuse of triptans in chronic migraine (CM) Methods: Case-control study. We included CM patients firstly referred to aheadache unit. Patients were cases or controls ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1842733

    authors: Martínez-Pías E,García-Azorín D,Minguez-Olaondo A,Trigo J,Sierra Á,Ruiz M,Guerrero ÁL

    更新日期:2021-01-01 00:00:00

  • New-onset epilepsy: considerations for initial and follow-up MRI to detect brain tumor.

    abstract::Seizures are often the presenting symptoms of a cerebral tumor and may precede its diagnosis by many years. The article under evaluation searched two large English registries for patients admitted for new-onset epilepsy. The risk of subsequently being diagnosed with a malignant brain tumor was found to be 26-fold high...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.80

    authors: Schucht P,Duffau H

    更新日期:2011-08-01 00:00:00

  • Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1378098

    authors: Ruggieri S,Tortorella C,Gasperini C

    更新日期:2017-11-01 00:00:00

  • Evaluation of malnutrition in patients with nervous system disease.

    abstract::Nutritional deficiencies are independent risk factors for adverse outcomes in patients with nervous system disease. Patients with nervous system disease can often become malnourished due to swallowing difficulties or unconsciousness. This malnourishment increases hospitalization duration; average total hospital cost; ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.957184

    authors: Li F,Liu YW,Wang XF,Liu GW

    更新日期:2014-10-01 00:00:00

  • Repetitive transcranial magnetic stimulation as treatment for anxiety disorders.

    abstract::Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive and generally well-tolerated method of focally stimulating brain regions. It has been shown to be efficacious in the treatment for depression, but only to a limited degree. It has also been investigated for the treatment of some anxiety disorders, pa...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.8.10.1449

    authors: Pigot M,Loo C,Sachdev P

    更新日期:2008-10-01 00:00:00

  • Gene therapy applications for the treatment of neuropathic pain.

    abstract::Neuropathic pain is notoriously difficult to treat; currently available pharmaceutical drugs result in moderate analgesia in approximately a third of patients. As our understanding of the biological processes involved in the establishment and maintenance of neuropathic pain increases, so does the development of novel ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.5.487

    authors: Goss JR,Goins WF,Glorioso JC

    更新日期:2007-05-01 00:00:00

  • Evaluating and managing severe headache in the emergency department.

    abstract::Introduction: Headache is the fifth most common reason to visit an emergency department (ED). In most of the cases, headache is benign and has a primary origin, with migraine as the most common diagnosis. Inappropriate use of ED for non-emergency conditions causes overcrowding, unnecessary testing, and increased medic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1863148

    authors: Luciani M,Negro A,Spuntarelli V,Bentivegna E,Martelletti P

    更新日期:2021-01-04 00:00:00

  • Poor insight into schizophrenia: contributing factors, consequences and emerging treatment approaches.

    abstract::Poor insight or unawareness of illness has been commonly observed in schizophrenia and has been long recognized as a potent barrier to treatment adherence and a risk factor for a range of poorer outcomes. Paradoxically, the achievement of insight often poses a different set of problems including depression and low sel...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.811150

    authors: Lysaker PH,Vohs J,Hillis JD,Kukla M,Popolo R,Salvatore G,Dimaggio G

    更新日期:2013-07-01 00:00:00

  • An update on the recognition and treatment of non-convulsive status epilepticus in the intensive care unit.

    abstract:INTRODUCTION:Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1369880

    authors: Kinney MO,Kaplan PW

    更新日期:2017-10-01 00:00:00

  • Developing drug strategies for the neuroprotective treatment of acute ischemic stroke.

    abstract::Developing new treatment strategies for acute ischemic stroke in the last twenty years has offered some important successes, but also several failures. Most trials of neuroprotective therapies have been uniformly negative to date. Recent research has reported how excitatory amino acids act as the major excitatory neur...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1101345

    authors: Tuttolomondo A,Pecoraro R,Arnao V,Maugeri R,Iacopino DG,Pinto A

    更新日期:2015-01-01 00:00:00

  • Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.

    abstract::Multiple sclerosis (MS) is an autoimmune disorder characterized by CNS inflammation, demyelination and cellular damage with atrophy. Most patients with MS initially present with a relapsing-remitting course, with periodic episodes of neurologic symptomatology that do not follow a predictable pattern. In order to maint...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.135

    authors: Fox EJ

    更新日期:2010-12-01 00:00:00

  • The use of sodium oxybate to treat narcolepsy.

    abstract::Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepressants, and the res...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.42

    authors: Mayer G

    更新日期:2012-05-01 00:00:00

  • Anaplastic glioma: current treatment and management.

    abstract::Anaplastic glioma (AG) is divided into three morphology-based groups (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) as well as three molecular groups (glioma-CpG island methylation phenotype [G-CIMP] negative, G-CIMP positive non-1p19q codeleted tumors and G-CIMP positive codeleted...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1042455

    authors: Le Rhun E,Taillibert S,Chamberlain MC

    更新日期:2015-06-01 00:00:00

  • Sumatriptan/naproxen sodium combination for the treatment of migraine.

    abstract::Sumatriptan 85 mg with naproxen sodium 500 mg, a combination tablet for the acute treatment of migraine, is approved in the USA. It is likely that triptan/NSAID combination benefits are a class effect, although the majority of data are on sumatriptan and naproxen sodium. The combination tablet demonstrated superior ef...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.9.1289

    authors: Cleves C,Tepper SJ

    更新日期:2008-09-01 00:00:00

  • Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers.

    abstract::Alzheimer's disease is an age-related dementia and its incidence is rising in developed countries as the population ages. Amyloid plaques and tau-rich neurofibrillary tangles are pathologic hallmarks of the disease. Treatment is symptomatic, consisting of compounds that block enzymatic acetylcholine degradation (acety...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.1.97

    authors: Silverberg GD,Mayo M,Saul T,Carvalho J,McGuire D

    更新日期:2004-01-01 00:00:00

  • New therapeutics in spine metastases.

    abstract::The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.831

    authors: Bilsky MH

    更新日期:2005-11-01 00:00:00

  • Post-stroke pain.

    abstract::Pain is one of the most troublesome sequelae of stroke, occurring in 19-74% of patients. A portion of this post-stroke pain is caused by the brain lesion itself; this is called 'central post-stroke pain' (CPSP). Although the prevalence of CPSP among stroke patients is low (1-8%), the persistent, often treatment-refrac...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.19

    authors: Kim JS

    更新日期:2009-05-01 00:00:00

  • Pathogenic role of mitochondrial [correction of mitochondral] amyloid-beta peptide.

    abstract::Metabolic dysfunction is one of the early features in Alzheimer's disease (AD) affected brain. Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD. However, the pathogenic role of Abeta remains to be determined. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.11.1517

    authors: Chen JX,Yan SD

    更新日期:2007-11-01 00:00:00

  • Recent genetic advances in ADHD and diagnostic and therapeutic prospects.

    abstract::Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.4.453

    authors: Hawi Z,Kirley A,Lowe N,Fitzgerald M,Gill M

    更新日期:2003-07-01 00:00:00

  • Current concept of anxiety: implications from Darwin to the DSM-V for the diagnosis of generalized anxiety disorder.

    abstract::This article proposes a revision of the historical evolution of the concepts of generalized anxiety disorder (GAD). Currently, Darwin's evolutionary theory is the hegemonic paradigm for modern science and influences research on mental disorders. Throughout the 20th Century, the editions of the Diagnostic and Statistic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.101

    authors: Coutinho FC,Dias GP,do Nascimento Bevilaqua MC,Gardino PF,Pimentel Rangé B,Nardi AE

    更新日期:2010-08-01 00:00:00

  • Disease-specific therapy of idiopathic inflammatory demyelinating disorders.

    abstract::Central nervous system idiopathic inflammatory demyelinating disorders are a heterogenous group of diseases that share inflammation and demyelination as key features. Although the exact pathophysiology remains to be fully unveiled, these conditions are challenging to clinicians who seek specific therapeutic options fo...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.101

    authors: Khoshnam M,Freedman MS

    更新日期:2012-09-01 00:00:00

  • Gene therapy for Parkinson's disease.

    abstract::Advances in molecular biology and virology in recent years have enabled the technology of gene transfer to proceed forward. Parkinson's disease (PD) is a particularly appropriate target for gene therapy since the brain pathology is fully characterized and relatively well circumscribed largely within the nigrostriatal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.8.957

    authors: Mochizuki H

    更新日期:2007-08-01 00:00:00

  • Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders.

    abstract::The 10th Global College of Neuroprotection and Neuroregeneration Annual Conference in collaboration with the 6th International Association of Neurorestoratology VI Intercontinental Hotel, Bucharest, Romania, 4-7 April 2013 The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2013.836297

    authors: Sharma HS,Muresanu DF,Sharma A

    更新日期:2013-10-01 00:00:00

  • Assessment, pathophysiology and treatment of fatigue in multiple sclerosis.

    abstract::This review will update current views of the physiopathology and treatment of fatigue in multiple sclerosis. Fatigue is a common symptom in multiple sclerosis, being reported by about a third of the patients. For many of them it is the most disabling symptom, with negative consequences on working activity and daily li...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.6.867

    authors: Comi G,Leocani L

    更新日期:2002-11-01 00:00:00

  • Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

    abstract::The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.13.17

    authors: Deiß A,Brecht I,Haarmann A,Buttmann M

    更新日期:2013-03-01 00:00:00